Main Navigation

Mercia
  • Ventures
  • Debt
  • Private equity
  • Team
  • Contact us
  • About us
  • Investment strategies
  • Investor area
    • PLC
    • EIS
    • VCT
  • Contact us

Audience

|

Change

  • Ventures
  • Debt
  • Private equity
  • Team
  • Contact us
  • About us
    • About us
      • Our history
      • Our vision and values
      • University partnerships
    • Team
    • Careers
    • Portfolio
    • Sustainability
  • Strategies
    • Our investment strategy
      • Our funds
    • Strategic assets
    • Property development finance
    • EIS & VCT
  • For shareholders
    • Share price
    • Board of directors
    • Financial reports & presentations
    • Regulatory news
    • Corporate governance
    • AIM Rule 26
    • Organisational structure
    • Annual Report
    • VCT
      • Northern Venture Trust
      • Northern 2 VCT
      • Northern 3 VCT
  • Insights & Research
    • Hub
  • Ventures
  • Debt
  • Private equity
  • Team
  • Contact us
  • About us
  • Investment strategies
  • Investor area
    • PLC
    • EIS
    • VCT
  • Contact us
  • About us
    • About us
      • Our history
      • Our vision and values
      • University partnerships
    • Team
    • Careers
    • Portfolio
    • Sustainability
  • Strategies
    • Our investment strategy
      • Our funds
    • Strategic assets
    • Property development finance
    • EIS & VCT
  • For shareholders
    • Share price
    • Board of directors
    • Financial reports & presentations
    • Regulatory news
    • Corporate governance
    • AIM Rule 26
    • Organisational structure
    • Annual Report
    • VCT
      • Northern Venture Trust
      • Northern 2 VCT
      • Northern 3 VCT
  • Insights & Research
    • Hub

Announcements

Exam marking platform raises £1.6m to target US growth
Product information platform targets US growth after £4m funding
Tagomics raises £6.7m to improve disease diagnosis
Spin-out raises £7.5m for novel treatment for blocked arteries
Webinar | Reducing your clients income tax with Mercia’s KI EIS fund
MIP Discovery raises £7m to drive commercialisation in cell and gene therapy
From skins to sporrans – leather firm set to target new markets
Biotech firm raises £2.3m for lab models that help avoid animal testing
Metrology firm secures funding to launch new demo centre
Spin-out raises £1.4m for lung test to aid early diagnosis of asthma
  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • Next
Loading...
Loading...

Disclaimer

Which of these options best describes you?

Please wait...
Accept

Disclaimers

Which of these options best describes you?

Please wait...
Accept

© 2026 Mercia Asset Management

  • Contact us
  • Privacy policy
  • Terms and conditions
  • Modern Slavery Statement
  • Diversity, Equity & Inclusion Policy
  • Sustainability

Mercia Asset Management PLC is registered in England and Wales: 09223445. Its subsidiaries, Mercia Fund Management Limited, Mercia Regional Ventures Limited, Mercia Business Loans Limited and Frontier Development Capital Limited are authorised and regulated by the Financial Conduct Authority.

Loading...
Loading...

Disclaimer

Which of these options best describes you?

Please wait...
Accept

Disclaimers

Which of these options best describes you?

Please wait...
Accept